Differences in risk factors of malignancy between men and women with type 2 diabetes: A retrospective case-control study.

Oncotarget · 2017 · PMC5620147 · PMID 28978007

Europe PMC DOI

hedged sentences

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

did not reach statistical significanceP = 0.068so close (0.05 < p ≤ 0.1)

69.4% respectively), but in this case difference did not reach statistical significance, P = 0.068.

also in 111,027 other papers

highly significantno p-value reported

Highly significant reduction of cancer risk among metformin users, consistent among men and women observed in our study is in line with the results of meta-analyses published in recent years, which also demonstrated protective effect of metformin on cancer incidence and mortality [ 17 – 20 ] irrespective of gender [ 20 ].

also in 132,142 other papers

borderline significantno p-value reported

In the univariate analysis aspirin use demonstrated borderline significant protective effect on the risk of malignancy in male subjects (Tables 1 and 2 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.